Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Buys Out Neptunus Stake in Chinese Vaccines JV; Are New Pharmacopoeia Standards At Play?

This article was originally published in PharmAsia News

Executive Summary

In an effort to increase its footprint in the Chinese vaccine market, GlaxoSmithKline PLC will acquire the remaining 51% equity stake in its joint venture with China's Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. for $39 million in cash, the companies announced June 14

You may also be interested in...



China’s Best Shot: GSK, Novartis Gear Up For Vaccine Prime Time

With its large population, one-child policy and increasing emphasis on preventative care, China is poised for a vaccine boom. The catalyst for growth may come from the expected modernization of the country’s massive national immunization program.

Merck Expands Deal With Chinese Vaccines Firm As MNCs Look To Recover From China Pharmacopeia Issue

Merck is including its vaccine distribution partner Chongqing Zhifei in its development plan for at least two vaccines in China, while global firms regain a footing after new standards in the Chinese Pharmacopeia stilted their market growth.

Merck Expands Deal With Chinese Vaccines Firm As MNCs Look To Recover From China Pharmacopeia Issue

Merck is including its vaccine distribution partner Chongqing Zhifei in its development plan for at least two vaccines in China, while global firms regain a footing after new standards in the Chinese Pharmacopeia stilted their market growth.

Related Content

UsernamePublicRestriction

Register

SC078199

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel